Evidence map›Paper›PMID 30397320›Full record

ArticleNature chemistry2019

A chemoselective strategy for late-stage functionalization of complex small molecules with polypeptides and proteins.

Daniel T Cohen, Chi Zhang, Colin M Fadzen, Alexander J Mijalis, Liana Hie, Kenneth D Johnson, Zachary Shriver, Obadiah Plante, Scott J Miller, Stephen L Buchwald and 1 more

Abstract read
In one paragraph

Article in Nature chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Ultrafast Au(III)-Mediated Arylation of Cysteine.Journal of the American Chemical Society · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.International journal of molecular sciences · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Organometallic AlaChem catalysis · 2021
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daniel T CohenDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. daniel.t.cohen@abbvie.com.
Chi ZhangDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
Colin M FadzenDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
Alexander J MijalisDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
Liana HieDepartment of Chemistry, Yale University, New Haven, CT, USA.
Kenneth D JohnsonVisterra Inc., Cambridge, MA, USA.
Zachary ShriverVisterra Inc., Cambridge, MA, USA.
Obadiah PlanteVisterra Inc., Cambridge, MA, USA.
Scott J MillerDepartment of Chemistry, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-7817-1318
Stephen L BuchwaldDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA.
Bradley L PenteluteDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. blp@mit.edu.

Funding

Metal-Catalyzed Methods for Organic SynthesisR35GM122483 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI STEPHEN L BUCHWALD · 2017 to 2026
$11.4M
CATALYTIC METHODS FOR ORGANIC SYNTHESISR37GM046059 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BUCHWALD, STEPHEN L · 2000 to 2009
$8.1M
EARLY TRANSITION METAL CATALYSTS IN ORGANIC SYNTHESISR01GM046059 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BUCHWALD, STEPHEN L · 1992 to 2016
$5.4M
Site-Selective Catalysis for Organic SynthesisR37GM068649 · NIGMS · YALE UNIVERSITY · PI MILLER, SCOTT J · 2011 to 2018
$2.7M
Cysteine ArylationR01GM110535 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI PENTELUTE, BRADLEY LETHER · 2014 to 2018
$1.5M
Acquisition of Octet Biolayer Interferometry system for MIT biophysics facilityS10OD016326 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI IMPERIALI, BARBARA · 2014 to 2014
$180k
Development of New Metal_Catalyzed Hydroacylation and Hydroarylation ProcessesF32GM108294 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI COHEN, DANIEL TZVI · 2013 to 2015
$153k
Chemically Modified Peptide Agents for Next-Generation Conjugate Therapies to Treat Duchenne Muscular DystrophyF30HD093358 · NICHD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FADZEN, COLIN MACLAINE · 2017 to 2019
$142k
Development of Site-Selective Glycosylation of Unprotected SugarsF32GM122204 · NIGMS · YALE UNIVERSITY · PI HIE, LIANA · 2017 to 2017
$56k
NICHD NIH HHS F30 HD093358NIGMS NIH HHS F32 GM108294NIGMS NIH HHS F32 GM122204NIGMS NIH HHS R01 GM046059NIGMS NIH HHS R01 GM110535NIGMS NIH HHS R35 GM122483NIGMS NIH HHS R37 GM046059NIGMS NIH HHS R37 GM068649NIH HHS S10 OD016326
6 · The paper itself

Abstract

Conjugates between proteins and small molecules enable access to a vast chemical space that is not achievable with either type of molecule alone; however, the paucity of specific reactions capable of functionalizing proteins and natural products presents a formidable challenge for preparing conjugates. Here we report a strategy for conjugating electron-rich (hetero)arenes to polypeptides and proteins. Our bioconjugation technique exploits the electrophilic reactivity of an oxidized selenocysteine residue in polypeptides and proteins, and the electron-rich character of certain small molecules to provide bioconjugates in excellent yields under mild conditions. This conjugation chemistry enabled the synthesis of peptide-vancomycin conjugates without the prefunctionalization of vancomycin. These conjugates have an enhanced in vitro potency for resistant Gram-positive and Gram-negative pathogens. Additionally, we show that a 6 kDa affibody protein and a 150 kDa immunoglobulin-G antibody could be modified without diminishing bioactivity.

Indexed as

AlkenesAntimicrobial Cationic PeptidesBacteriaBiochemistryImmunoconjugatesImmunoglobulin GOxidation-ReductionPeptidesProteinsSelenocysteineVancomycinAlkenesAntimicrobial Cationic PeptidesImmunoconjugatesImmunoglobulin GPeptidesProteinsSelenocysteineVancomycin

Identifiers

PMID30397320
PMCPMC6454892

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.